Filing Flows › Aquestive Therapeutics (AQST) › How it makes money
How Aquestive Therapeutics (AQST) makes money
Aquestive Therapeutics (AQST) made $7.6M of revenue in the third quarter 2026 (Q3 2026), -41% from a year earlier. Manufacture and supply revenue brought in $6.7M (88%); License and Royalty Revenue brought in $824K (11%); Co-development and research fees brought in $74K (1%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Manufacture and supply revenue | $6.7M | 88.1% | -44% | -42% |
| License and Royalty Revenue | $824K | 10.9% | -38% | -21% |
| Co-development and research fees | $74K | 1.0% | -87% | -75% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $7.6M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $7.6M | -41% |
| Q2 2026 | $13.8M | +38% |
| Q1 2026 | $14.4M | +66% |
| Q4 2025 | $13.0M | +10% |
| Q3 2025 | $12.8M | -5% |
| Q2 2025 | $10.0M | -50% |
| Q1 2025 | $8.7M | -28% |
From Aquestive Therapeutics' 10-Q filed Nov 3, 2026 (on EDGAR).
Questions
How does Aquestive Therapeutics make money?
Aquestive Therapeutics (AQST) made $7.6M of revenue in the third quarter 2026 (Q3 2026), -41% from a year earlier. Manufacture and supply revenue brought in $6.7M (88%); License and Royalty Revenue brought in $824K (11%); Co-development and research fees brought in $74K (1%).
What is Aquestive Therapeutics' biggest business?
Manufacture and supply revenue: $6.7M in the third quarter 2026, 88% of revenue, -42% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.